A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy. / Wulf, Hans Christian; Al-Chaer, Rami Nabil; Glud, Martin; Philipsen, Peter Alshede; Lerche, Catharina Margrethe.

In: Pharmaceuticals, Vol. 14, No. 5, 433, 05.2021.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Wulf, HC, Al-Chaer, RN, Glud, M, Philipsen, PA & Lerche, CM 2021, 'A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy', Pharmaceuticals, vol. 14, no. 5, 433. https://doi.org/10.3390/ph14050433

APA

Wulf, H. C., Al-Chaer, R. N., Glud, M., Philipsen, P. A., & Lerche, C. M. (2021). A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy. Pharmaceuticals, 14(5), [433]. https://doi.org/10.3390/ph14050433

Vancouver

Wulf HC, Al-Chaer RN, Glud M, Philipsen PA, Lerche CM. A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy. Pharmaceuticals. 2021 May;14(5). 433. https://doi.org/10.3390/ph14050433

Author

Wulf, Hans Christian ; Al-Chaer, Rami Nabil ; Glud, Martin ; Philipsen, Peter Alshede ; Lerche, Catharina Margrethe. / A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy. In: Pharmaceuticals. 2021 ; Vol. 14, No. 5.

Bibtex

@article{2bdfea1b975d49fe9ffc41c65927a98f,
title = "A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy",
abstract = "The high incidence of sunlight-induced human skin cancers reveals a need for more effective photosensitizing agents. In this study, we compared the efficacy of prophylactic photodynamic therapy (PDT) when methylene blue (MB), riboflavin (RF), or methyl aminolevulinate (MAL) were used as photosensitizers. All mice in four groups of female C3.Cg/TifBomTac hairless immunocompetent mice (N = 100) were irradiated with three standard erythema doses of solar-simulated ultraviolet radiation (UVR) thrice weekly. Three groups received 2 x 2 prophylactic PDT treatments (days 45 + 52 and 90 + 97). The PDT treatments consisted of topical administration of 16% MAL, 20% MB, or 20% RF, and subsequent illumination that matched the photosensitizers' absorption spectra. Control mice received no PDT. We recorded when the first, second, and third skin tumors developed. The pattern of tumor development after MB-PDT or RF-PDT was similar to that observed in irradiated control mice (p > 0.05). However, the median times until the first, second, and third skin tumors developed in mice given MAL-PDT were significantly delayed, compared with control mice (256, 265, and 272 vs. 215, 222, and 230 days, respectively; p < 0.001). Only MAL-PDT was an effective prophylactic treatment against UVR-induced skin tumors in hairless mice.",
keywords = "PDT, methyl aminolevulinate, methylene blue, riboflavin, photosensitizing agents, ultraviolet radiation, skin tumors, prophylactic treatment, hairless mice, BASAL-CELL CARCINOMA, ACTINIC KERATOSES, DELIVERY, PHOTOCARCINOGENESIS, PHOTOACTIVATION, MULTICENTER, EXPOSURE, SURGERY",
author = "Wulf, {Hans Christian} and Al-Chaer, {Rami Nabil} and Martin Glud and Philipsen, {Peter Alshede} and Lerche, {Catharina Margrethe}",
year = "2021",
month = may,
doi = "10.3390/ph14050433",
language = "English",
volume = "14",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "M D P I AG",
number = "5",

}

RIS

TY - JOUR

T1 - A Skin Cancer Prophylaxis Study in Hairless Mice Using Methylene Blue, Riboflavin, and Methyl Aminolevulinate as Photosensitizing Agents in Photodynamic Therapy

AU - Wulf, Hans Christian

AU - Al-Chaer, Rami Nabil

AU - Glud, Martin

AU - Philipsen, Peter Alshede

AU - Lerche, Catharina Margrethe

PY - 2021/5

Y1 - 2021/5

N2 - The high incidence of sunlight-induced human skin cancers reveals a need for more effective photosensitizing agents. In this study, we compared the efficacy of prophylactic photodynamic therapy (PDT) when methylene blue (MB), riboflavin (RF), or methyl aminolevulinate (MAL) were used as photosensitizers. All mice in four groups of female C3.Cg/TifBomTac hairless immunocompetent mice (N = 100) were irradiated with three standard erythema doses of solar-simulated ultraviolet radiation (UVR) thrice weekly. Three groups received 2 x 2 prophylactic PDT treatments (days 45 + 52 and 90 + 97). The PDT treatments consisted of topical administration of 16% MAL, 20% MB, or 20% RF, and subsequent illumination that matched the photosensitizers' absorption spectra. Control mice received no PDT. We recorded when the first, second, and third skin tumors developed. The pattern of tumor development after MB-PDT or RF-PDT was similar to that observed in irradiated control mice (p > 0.05). However, the median times until the first, second, and third skin tumors developed in mice given MAL-PDT were significantly delayed, compared with control mice (256, 265, and 272 vs. 215, 222, and 230 days, respectively; p < 0.001). Only MAL-PDT was an effective prophylactic treatment against UVR-induced skin tumors in hairless mice.

AB - The high incidence of sunlight-induced human skin cancers reveals a need for more effective photosensitizing agents. In this study, we compared the efficacy of prophylactic photodynamic therapy (PDT) when methylene blue (MB), riboflavin (RF), or methyl aminolevulinate (MAL) were used as photosensitizers. All mice in four groups of female C3.Cg/TifBomTac hairless immunocompetent mice (N = 100) were irradiated with three standard erythema doses of solar-simulated ultraviolet radiation (UVR) thrice weekly. Three groups received 2 x 2 prophylactic PDT treatments (days 45 + 52 and 90 + 97). The PDT treatments consisted of topical administration of 16% MAL, 20% MB, or 20% RF, and subsequent illumination that matched the photosensitizers' absorption spectra. Control mice received no PDT. We recorded when the first, second, and third skin tumors developed. The pattern of tumor development after MB-PDT or RF-PDT was similar to that observed in irradiated control mice (p > 0.05). However, the median times until the first, second, and third skin tumors developed in mice given MAL-PDT were significantly delayed, compared with control mice (256, 265, and 272 vs. 215, 222, and 230 days, respectively; p < 0.001). Only MAL-PDT was an effective prophylactic treatment against UVR-induced skin tumors in hairless mice.

KW - PDT

KW - methyl aminolevulinate

KW - methylene blue

KW - riboflavin

KW - photosensitizing agents

KW - ultraviolet radiation

KW - skin tumors

KW - prophylactic treatment

KW - hairless mice

KW - BASAL-CELL CARCINOMA

KW - ACTINIC KERATOSES

KW - DELIVERY

KW - PHOTOCARCINOGENESIS

KW - PHOTOACTIVATION

KW - MULTICENTER

KW - EXPOSURE

KW - SURGERY

U2 - 10.3390/ph14050433

DO - 10.3390/ph14050433

M3 - Journal article

C2 - 34063120

VL - 14

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 5

M1 - 433

ER -

ID: 272404503